Galectin Therapeutics (NASDAQ:GALT - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.
Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last released its quarterly earnings data on Monday, March 31st. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.03). On average, analysts expect Galectin Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Galectin Therapeutics Stock Performance
GALT opened at $1.32 on Wednesday. Galectin Therapeutics has a fifty-two week low of $0.73 and a fifty-two week high of $3.28. The company has a fifty day moving average of $1.43 and a two-hundred day moving average of $1.67. The stock has a market capitalization of $83.40 million, a price-to-earnings ratio of -1.81 and a beta of 0.62.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a "neutral" rating on shares of Galectin Therapeutics in a research note on Wednesday, April 2nd.
Read Our Latest Report on GALT
Institutional Trading of Galectin Therapeutics
A hedge fund recently raised its stake in Galectin Therapeutics stock. Bank of America Corp DE lifted its stake in shares of Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) by 101.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,358 shares of the company's stock after purchasing an additional 19,316 shares during the period. Bank of America Corp DE owned about 0.06% of Galectin Therapeutics worth $49,000 as of its most recent filing with the Securities & Exchange Commission. 11.68% of the stock is currently owned by institutional investors.
About Galectin Therapeutics
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Galectin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.
While Galectin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
